Risk assessment model for heart failure in Chinese patients with Takayasu's arteritis

Yu-Jiao Wang1, Li-Li Ma1,2, Yun Liu1

  • 1Department of Rheumatology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China.

Insights

A risk assessment model was developed to identify heart failure (HF) risk in Takayasu

Area of Science:

  • Cardiology
  • Rheumatology
  • Vascular Medicine

Background:

  • Takayasu's arteritis (TAK) is a rare, chronic inflammatory disease affecting large arteries.
  • Heart failure (HF) is a significant complication in TAK patients, necessitating early identification and risk stratification.
  • Understanding risk factors for HF in TAK is crucial for timely intervention and improved patient outcomes.

Purpose of the Study:

  • To construct and validate a predictive risk assessment model for heart failure (HF) in patients diagnosed with Takayasu's arteritis (TAK).
  • To identify key clinical and laboratory risk factors associated with the development of HF in TAK patients.

Main Methods:

  • A cohort of 365 TAK patients was divided into training (2:1 ratio) and validation sets.
  • Logistic regression analysis was employed to identify HF risk factors and develop a scoring algorithm.
  • The model's predictive accuracy was assessed using Area Under the Curve (AUC) in both training and validation sets.

Main Results:

  • Heart failure was observed in 20.27% of TAK patients.
  • Identified risk factors for HF in TAK include: onset age >38 years, elevated serum TNF-α (>10 pg/ml), aortic valve involvement, coronary artery involvement, and pulmonary hypertension.
  • The developed risk assessment model demonstrated high accuracy (AUC 0.88-0.90 in training, 0.88-0.89 in validation sets).

Conclusions:

  • A validated risk assessment model can effectively identify TAK patients at high risk for developing heart failure.
  • The model, incorporating factors like age, TNF-α levels, and specific cardiac involvements, aids clinicians in anticipating HF complications.
  • Early identification of HF risk in TAK patients allows for targeted management strategies and potentially mitigates adverse cardiovascular events.
Abstract

Related Concept Videos

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
179
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
98
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
102
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
640
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
82
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
183